 Liposomal transfection method |
| The object of the present invention is thus a method for transfecting a cell with a nucleic acid ... |
|
| Antihelminthic anthraquinones and method of use thereof |
| OF THE INVENTION All patents, patent applications, government publications, government regulations,... |
|
| Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA |
| The invention is directed to a new method of inducing viral mutagenesis which is useful in cell ... |
|
| 2'-Fluoronucleosides |
| OF THE INVENTION The invention as disclosed herein is a compound, method and composition for the ... |
|
| Nucleoside compounds |
| Where the following terms are used in this specification, they are used as defined below. The ... |
|
| Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| OF THE INVENTION In one embodiment, the viral infection is chosen from Flaviviridea viral ... |
|
| Monocyclic L-nucleosides, analogs and uses thereof |
| Where the following terms are used in this specification, they are used as defined below. The term ... |
|
| Storage medium storing catalog information and corresponding audio data |
| It is an object of the present invention to provide a storage medium for storing catalog ... |
|
| Nucleoside compounds and uses thereof |
| The present invention is directed to nucleoside analogs and related compounds, including their ... |
|
| Composition and method for inhibiting platelet aggregation |
| OF THE INVENTION This invention is provides a method of preventing or treating diseases or ... |
|
|
A3AR agonists for the treatment of inflammatory arthritis
| Details |
Inventors: Fishman, Pnina;
Assignee: Can-Fite Biopharma Ltd. Israel (Petach Tikva, IL)
Primary Examiner: Lewis; Patrick
Assistant Examiner:
Attorney, Agent or Firm: Browdy and Neimark, PLLC
The present invention concerns a method for the treatment of inflammatory arthritis, and in particular rheumatoid arthritis, by administering to the subject specific low dosages of N6-(3-iodobenzyl)-adenosine 5'-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (CL-IB-MECA). |
|
DETAILED DESCRIPTION The invention is described in the following SUMMARY with reference to a therapeutic method for the treatment of inflammatory arthritis.
It should be noted that in addition to said therapeutic method, also encompassed within Me present invention is an oral pharmaceutical composition for the treatment of inflammatory arthritis that comprises an effective amount of the active agents as defined bellow and a carrier pharmaceutically acceptable for oral administration; as well as the use of said active agent for the preparation of a pharmaceutical composition for oral administration to a subject suffering of inflammatory arthritis and being in need for an anti-inflammatory treatment.
As will be appreciated, the effective amount in the pharmaceutical composition will depend on the intended therapeutic regiment and the desired therapeutic dose.
By way of example were the dose is 1 mg per day and the desired administration regiment is once daily administration, the amount of active agent in the pharmaceutical composition will be 1 mg where it is intended to divide his daily dose in 2 daily administrations, the amount of the active agent in he pharmaceutical composition will be 0.
5 mg.
In the following, the term "anti-inflammatory" will be used to denote the disease modifying effect of IB-MECA or Cl-IB-MECA in alleviating the inflammatory response in inflammatory arthritis.
The anti-inflammatory response may be determined on the basis of histological parameters, the extent of swollen and tender joints, motility parameters, reduction in pain, a number of different overall performance scoring systems, etc.
The present invention is based on the surprising finding that oral administration of specific A3-receptor agonists, N6-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (IB-MECA) or 2-chloro-N.
sup.
6-(3-iodobenzyl)-adenosine-5'-N-methyl-uronamide (Cl-IB-MECA) alleviated symptoms of inflammatory arthritis at doses which are lower than those previously described, particularly by Szabo et
|
|
Gene Therapy 
